Erratum: Establishing medical plausibility in the context of orphan medicines designation in the European Union(Orphanet Journal of Rare Diseases(2015)9(175)10.1186/s13023-014-0175-8);Establishing medical plausibility in the context of orphan medicines designation in the European Union

Orphanet Journal of Rare Diseases

Volumn 9, Issue 1, 2014, Pages

  Tsigkos, Stelios ^a   Mariz, Segundo ^a   Llinares, Jordi ^a   Fregonese, Laura ^a   Aarum, Stiina ^a   Frauke, Naumann Winter ^b   Westermark, Kerstin ^c   Sepodes, Bruno ^d  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b Bundesinstitut fur Arzneimittel und Medizinproducte   (Germany)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

^d RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

ALAGILLE SYNDROME; ALTITUDE DISEASE; ARTICLE; COMMITTEE OF ORPHAN MEDICINAL PRODUCT; DRUG APPROVAL; DRUG INDICATION; DRUG INDUSTRY; DRUG MANUFACTURE; DUCHENNE MUSCULAR DYSTROPHY; EOSINOPHILIC ESOPHAGITIS; EPIDERMOLYSIS BULLOSA; EUROPEAN UNION; EVIDENCE BASED MEDICINE; FRAGILE X SYNDROME; GLIOMA; GRAFT RECIPIENT; HEPATITIS C; IMMUNE DEFICIENCY; INTENTION TO TREAT ANALYSIS; LUNG EDEMA; MEDICAL PLAUSIBILITY; NIEMANN PICK DISEASE; PHARMACY AND THERAPEUTICS COMMITTEE; PROTOCOL COMPLIANCE; SCHNITZLER SYNDROME; HUMAN; RARE DISEASES;

DRUG APPROVAL; EUROPEAN UNION; HUMANS; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 84942420438     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-015-0309-7     Document Type: Erratum

References (25)

1. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999; [ http://ec.europa.eu/health/files/eudralex/vol-1/reg-2000-141/reg-2000-141-en.pdf ]
2. Guideline on the Format and Content of Applications for Designation as Orphan Medicinal Products and on the Transfer of Designations from one Sponsor to another. ENTR/6283/00 Rev 4 March 2014; [ http://ec.europa.eu/health/files/orphanmp/2014-03-guideline-rev4-final.pdf ]
3. Recommendation on Elements Required to Support the Medical Plausibility and the Assumption of Significant Benefit for an Orphan Designation EMA/COMP/15893/2009; [ http://www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2010/07/WC500095341.pdf ]
4. Westermark K, Holm BB, Söderholm M, Llinares-Garcia J, Rivière F, Aarum S, Butlen-Ducuing F, Tsigkos S, Wilk-Kachlicka A, N'Diamoi C, Borvendég J, Lyons D, Sepodes B, Bloechl-Daum B, Lhoir A, Todorova M, Kkolos I, Kubáčková K, Bosch-Traberg H, Tillmann V, Saano V, Héron E, Elbers R, Siouti M, Eggenhofer J, Salmon P, Clementi M, Krieviņš D, Committee for Orphan Medicinal Products and the European Medicines: European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov 2011, 10:341-347.
5. European Medicines Agency. COMP: Agendas, minutes and meeting reports; [ http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/document-listing/document-listing-000201.jsp&mid=WC0b01ac0580028e78#section2 ]
6. Medical Aspects of Harsh Environments, Volume 2. Washington DC: Borden Institute, Walter Reed Army Medical Center; 2002:20307 [ http://www.dtic.mil/dtic/tr/fulltext/u2/a433963.pdf ]
7. Public summary of opinion on orphan designation Cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys for the treatment of high altitude pulmonary oedema EMA/COMP/39571/2013; [ http://www.ema.europa.eu/docs/en-GB/document-library/Orphan-designation/2013/03/WC500139555.pdf ]
8. Vanier MT: Niemann-Pick diseases. Handb Clin Neurol 2013, 113:1717-1721.
9. Lopez ME, Scott MP: Genetic dissection of a cell-autonomous neurodegenerative disorder: lessons learned from mouse models of Niemann-Pick disease type C. Diease Models Mech 2013, 6:1089-1100.
10. Vite CH, Ding W, Bryan C, O'Donnell P, Cullen K, Aleman D, Haskins ME, Van Winkle T: Clinical, electrophysiological, and serum biochemical measures of progressive neurological and hepatic dysfunction in feline Niemann-Pick type C disease. Pediatr Res 2008, 64:544-549.
11. Somers K, Royals M, Carstea E, Rafi M, Wenger D, Thralla M: Mutation analysis of feline Niemann-Pick C1 disease. Mol Genet Metab 2003, 79:99-103.
12. Jarmin S, Kymalainen H, Popplewell L, Dickson G: New developments in the use of gene therapy to treat Duchenne muscular dystrophy. Expert Opin Biol Ther 2014, 14:209-213.
13. Vaquer G, Rivière F, Mavris M, Bignami F, Llinares-Garcia J, Westermark K, Sepodes B: Animal models for metabolic, neuromuscular and ophthalmological rare diseases. Nat Rev Drug Discov 2013, 12:287-305.
14. Montiel-Equihua CA, Thrasher AJ, Gaspar HB: Development of gene therapy: potential in severe combined immunodeficiency due to adenosine deaminase deficiency. Stem Cells Cloning 2010, 3:1-12.
15. Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, Burks AW, Chehade M, Collins MH, Dellon ES, Dohil R, Falk GW, Gonsalves N, Gupta SK, Katzka DA, Lucendo AJ, Markowitz JE, Noel RJ, Odze RD, Putnam PE, Richter JE, Romero Y, Ruchelli E, Sampson HA, Schoepfer A, Shaheen NJ, Sicherer SH, Spechler S, Spergel JM, Straumann A: Eosinophilic esophagitis: Updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011, 128:3-20.
16. Gonzalez ME: Evaluation and treatment of the newborn with epidermolysis bullosa. Semin Perinatol 2013, 37:32-39.
17. Stupp R, Tonn JC, Brada M, Pentheroudakis G: ESMO Guidelines Working Group. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v190-v193.
18. Berniczei-Royko A, Chałas R, Mitura I, Nagy K, Prussak E: Medical and dental management of Alagille syndrome: A review. Med Sci Monit 2014, 20:476-480.
19. Turnpenny P, Ellard S: Allagile syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet 2012, 20:251-257.
20. Simon A, Asli B, Braun-Falco M, De Koning H, Fermand JP, Grattan C, Krause K, Lachmann H, Lenormand C, Martinez-Taboada V: Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy 2013, 68:562-568.
21. Vinaixa C, Rubín A, Aguilera V, Berenguer M: Recurrence of hepatitis C after liver transplantation. Ann Gastroenterol 2013, 26:304-313.
22. Hoeft F, Carter JC, Lightbody AA, Cody Hazlett H, Piven J, Reiss AL: Region-specific alterations in brain development in one- to three-year-old boys with fragile X syndrome. Proc Natl Acad Sci U S A 2010, 107:9335-9339.
23. D'Hulst C, Kooy RF: Fragile X syndrome: from molecular genetics to therapy. J Med Genet 2009, 46:577-584.
24. Berry-Kravis E: Mechanism-Based Treatments in Neurodevelopmental Disorders: Fragile X Syndrome. Pediatr Neurol 2014, 50:297-302.
25. European Medicines Agency: Rare disease (orphan) designations. [ http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/orphan-search.jsp&mid=WC0b01ac058001d12b ]